Orforglipron, Lillys first small-molecule oral GLP-1 receptor agonist in Phase 3, showed meaningful weight loss and glycemic control in adults with type 2 diabetes and overweight or obesity
Longer-term studies would be valuable for assessing the sustainability of the observed benefits and identifying any potential long-term effects
Research has found that there are a number of ways that people can improve their reproductive health
Risk of Legal Blindness and Ischemic Optic Neuropathy The GLP-1 cohort had a statistically significant reduction in risk of legal blindness, at all measured time periods, as compared to the control, with a 1-year hazard ratio of 0.589 (95% CI: 0.4760.728), 3-year HR of 0.677 (95% CI: 0.5830.788), and 5-year HR of 0.669 (95% CI: 0.5830.768)
Price per shot: $40 4-week treatment: $130 6-week treatment: $170 10-week treatment: $295 Immunity Boost Strengthen your immune system, especially during cold and flu season, with this powerful injection
We would have a personalised consultation with you to discuss the options
